Dr. Donna Pauler Ankerst

Weitere Informationen


  • Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr.
    Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial, Journal of the National Cancer Institute 98: 529-534, 2006.
  • Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MHA, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Kohli M, Bensen MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16, Journal of the National Cancer Institute 98: 516-521, 2006.
  • Ankerst DP, Engel J.
    Status of quality of life in breast cancer research before, during and beyond treatment. Expert Review of Pharmacoeconomics & Outcomes Research 6: 207-214, 2006.
  • Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL.
    Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood, April 4, epub ahead of print 2006.
  • Yildiz-Yesiloglu A, Ankerst DP.
    Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progress in Neuro-Psychopharmacology & Biological Psychiatry, May 3, epub ahead of print, 2006.
  • Crowley JC, Ankerst DP (eds).
    Handbook of statistics in clinical oncology, 2nd ed, Boca Raton: Chapman
    & Hall/CRC Taylor & Francis Group, 2006.
  • Etzioni RD, Howlader N, Shaw P, Ankerst DP, Penson DF, Goodman P, Tangen CM, Thompson IM.
    Long-term effect of finasteride on PSA levels: Results from the Prostate Cancer Prevention Trial. Journal of Urology 2005; 174(3):877-881.
  • Pauler DK.
    Bayes Factors. In Encyclopedia of Biostatistics, 2nd Edition, Volume 1, eds. P. Armitage and T. Colton, John Wiley & Sons 2005; 301-303.
  • Hansen LK, Feigl P, Modiano MR, Lopez JA, Escobedo Sluder S, Moinpour CM, Pauler DK, Meyskens FL.
    An Educational Program to Increase Cervical and Breast Cancer Screening in Hispanic Women: A Southwest Oncology Group Study. Cancer Nursing 2005; 28(1):47-53.
  • Hayden D, Pauler DK, Schoenfeld D.
    An Estimator for Treatment Comparisons among Survivors in Randomized Trials, Biometrics 2005; 61:305-310.
  • Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman P, Crowley JJ, Parnes HL, Coltman CA, Jr.
    The operating characteristics of prostate-specific antigen in a population with initial PSA of 3.0 ng/ml or lower, Journal of the American Medical Association 2005; 294:66-70.
  • Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, Ankerst DP, Disis ML.
    Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunology 2005; 6(1):17, doi:10.1186/1471-2172-6-17.
  • Pauler DK, Hardin J, Faulkner J, Leblanc M, Crowley JJ.
    Survival Analysis with Gene Expression Arrays. In Handbook of Statistics Vol. 23, eds. CR Rao and N Balakrishnan, Elsevier North Holland: Amsterdam 2004; 675-688.
  • Green S, Pauler DK.
    Statistics in Clinical Trials, Current Oncology Reports 2004; 6(1):36-41.
  • Yildiz A, Pauler DK, Sachs GS.
    Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. Journal of Affective Disorders 2004;78:157-162.
  • Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia SM, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr.
    Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. New England Journal of Medicine 2004; 350(22):2239-2246.
  • McGregor BA, Bowen DJ, Ankerst DP, Andersen MR, Yasui Y, McTiernan A. Optimism, perceived risk of breast cancer, and cancer worry among a community-based sample of women. Health Psychology 2004; 23(4):339-344.
  • Pauler DK, McCoy S, Moinpour C.
    Pattern mixture models for longitudinal quality of life studies in advanced-stage disease. Statistics in Medicine 2003;22:795-809.
  • Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW, Fisher RI.
    Health Status and Quality of Life in Patients with Early Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133, Journal of Clinical Oncology 2003; 21(18): 3512—3519.
  • Gatsonis C, Carriquiry A, Gelman A, Higdon D, Kass RE, Pauler DK, Verdinelli I (eds).
    Case Studies in Bayesian Statistics Vol. VI. Lecture Notes in Statistics 167. New York: Springer 2002.
  • Pauler DK, Laird NM.
    Non-linear hierarchical models for monitoring compliance. Statistics in Medicine 2002;21(2): 219-229.
  • Pauler DK, Finkelstein DM.
    Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Statistics in Medicine 2002; 21:3897-3911.
  • Pauler DK, Gower KB, Goodman PJ, Crowley JJ, Thompson IM.
    Biomarker-based methods for determining noncompliance in a prevention trial. Controlled Clinical Trials 2002; 23:675-685.
  • Skates SJ, Pauler DK, Jacobs IJ.
    Screening Based on the Risk of Cancer Calculation from Bayesian Hierarchical Change-Point Models of Longitudinal Markers. Journal of the American Statistical Association 2001; 96:429-439.
  • Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ.
    Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. Cancer Epidemiology, Biomarkers and Prevention 2001;10(5): 489-493.
  • Welt CK, Smith ZA, Pauler DK, Hall JE.
    Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. Journal of Clinical Endocrinology and Metabolism 2001;86(6): 2531-2537.